TuLip : Role of the Tumor Environment in Cancer-related Fat Loss

Cancer Clinical Trial

— TuLip  

Official title:

Study of the Tumor-adipose Tissue Dialogue: Role of Tumor Acidosis in the Induction of Adipocyte Lipolysis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05128318
• Other study ID #: TuLip
• Status: Recruiting
• Phase: N/A
• Start date: November 16, 2022
• Est. completion date: September 1, 2023

Study information

• Verified date: November 2022
• Source: Université Catholique de Louvain
• Contact: Laure Bindels, Professor
• Phone: +32 (2) 764 73 37
• Email: laure.bindels[@]uclouvain.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cancer cachexia is defined as a weight loss of more than 5% over the last 6 months, a loss of body fat and muscle atrophy. It is found in 80% of patients with advanced cancer. In this context, white adipose tissue is a particularly interesting target since its depletion precedes the loss of muscle mass, and is sufficient to induce a decrease in the response to anti-cancer treatments and in the survival of patients. This cachexia is associated with advanced tumors that present acidosis and metastasis. In this clinical study the investigators would like explore the acid environment effect on the human adipose tissue depletion and more specifically on adipocyte lipolysis. The main objective of the "TuLip" clinical study is therefore to validate in human subcutaneous and visceral adipocytes that factors secreted by tumor cells cultivated in acid tumor environment stimulate the release of lipids from adipose tissue. Adipocytes retrieves from this study will also be used to validate identified potential lipolytic factors derived from these cells.

Description:

This study is a monocentric clinical study. Patients with BMI < 30 kg/m2 will be recruited in the context of programmed abdominal surgery. In this context, subcutaneous and visceral adipose tissue pieces (1-2 cm3) will be collected to explore the lypolytic response of adipocytes ex-vivo to factors secreted by human cancer cell lines.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 39
• Est. completion date: September 1, 2023
• Est. primary completion date: September 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Programmed surgeries in the abdominal area in the Department of Surgery and Transplantation at Cliniques Universitaires Saint-Luc under the supervision of Prof. Dr. Benoit Navez.
• Hospitalization in the context of surgery
• Caucasian
• Age between 18 and 60 years (included).
• Body mass index less than 30 and greater than or equal to 18.5
• Programmed Nissen fundoplication (to treat hiatal hernia and gastroesophageal reflux) or cholecystectomy (to treat vesicular lithiasis).
• Adults capable of expressing their wishes.
• Understanding French

Exclusion Criteria:

• Body mass index below 18.5 and above 30.
• Patients with cancer, infection, autoimmune or inflammatory disease, metabolic syndrome.
• Patients with beta-blockers, hypoglycemics, anti-diabetics, hypolipidemics.
• Adults unable to express their will.
• Not understanding French
• Patients participating in a clinical trial for a drug treatment.

Related Conditions & MeSH terms

• Adipose Tissue
• Cachexia
• Cancer

Intervention

Procedure:
• Nissen Fundoplication, cholecystectomy
Collection of adipose tissue pieces in the context of programmed abdominal surgery to treat to treat hiatal hernia, gastroesophageal reflux or vesicular lithiasis. During the surgery treatment, adipose tissue of 1-2 cm3 will be collected for the protocol by laparoscopy by the surgeon in charge of the procedures.

Locations

Country	Name	City	State
Belgium	Cliniques universitaires Saint Luc	Brussel

Sponsors (2)

Lead Sponsor	Collaborator
Université Catholique de Louvain	Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the lipolytic response of adipocytes isolated from human visceral and subcutaneous adipose tissue to factors derived from cancer cells in acid environment by the glycerol measurement	Measure ex-vivo of the lipolysis of subcutaneous and visceral adipocytes in the presence of factors derived from cancer cells. The lipolysis will be assessed by the measure of glycerol (in mol/L) released by adipocytes.	Up to 100 days after the adipose tissue collection"
Primary	Evaluation of the lipolytic response of adipocytes isolated from human visceral and subcutaneous adipose tissue to factors derived from cancer cells in acid environment by the fatty acid measurement.	Measure ex-vivo of the lipolysis of subcutaneous and visceral adipocytes in the presence of factors derived from cancer cells. The lipolysis will be assessed by the measure of free fatty acids (in mol/L) released by adipocytes.	Up to 100 days after the adipose tissue collection"
Secondary	Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by western-blot	Protein analyses by western-blot (arbitrary units).	Up to 2 years after the adipose tissue collection
Secondary	Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by ELISA	Protein analyses by ELISA (mol/L or g/L).	Up to 2 years after the adipose tissue collection
Secondary	Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by proteomic analyses	Protein analyses via proteomic analyses (relative units).	Up to 2 years after the adipose tissue collection
Secondary	Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by biochemical analyses	Biochemical analyses (biochemical kits)	Up to 2 years after the adipose tissue collection
Secondary	Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by metabolomic analyses	Metabolomic analyses (arbitrary units or mol/L)	Up to 2 years after the adipose tissue collection
Secondary	Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by RNA sequencing	Measurement of gene expression by RNA sequencing (in counts) of RNA extracted from these ex-vivo cultured human adipocytes.	Up to 2 years after the adipose tissue collection
Secondary	Evaluation of the lipid metabolism, of adipocytes isolated from human visceral and subcutaneous adipose tissues to factors derived from cancer cells in acid environment, by RT-qPCR	Measurement of gene expression by RT-qPCR (in relative units) of RNA extracted from these ex-vivo cultured human adipocytes.	Up to 2 years after the adipose tissue collection